Schering-Plough has the rights to Santarus’ heartburn drug for the OTC market in the U.S. and Canada.

Santarus achieved a $5-million milestone in its license agreement with Schering-Plough HealthCare Products for its proton pump inhibitor (PPI).

The over-the-counter (OTC) license agreement gives Schering-Plough the right to develop, manufacture, and commercialize OTC products using Santarus’ PPI technology with the lower-dosage strength of 20 mg of omeprazole for heartburn-related indications in the U.S. and Canada. Santarus will continue to manufacture and sell its Zegerid prescription products in both 20-mg and 40-mg dosage strengths in the U.S.

In addition to the $15 million Santarus received upfront and this milestone fee, the company could receive up to $60 million in milestone payments plus low double-digit royalties. In turn, Santarus will be obligated to pay royalties to the University of Missouri on net sales of any such OTC products.

Previous articleQiagen and Joint Center for Structural Genomics Commercialize Crystallography Tool
Next articleCholesteryl Ester Transfer Protein Deficiency Leads to Abnormal Processing of Fats within Cell